BUDGET IMPACT ANALYSIS OF FITUSIRAN FOR THE TREATMENT OF HEMOPHILIA A AND B IN PEDIATRIC AND ADULT PATIENTS IN THE UNITED ARAB EMIRATES (ABU DHABI)
Author(s)
Sana Albelooshi, PharmD, BCOP, MBA1, Manal Rayyan, MSc. BCPS1, Mohammad Fahed Abdullah, MD2, Mousa Qatwaneh, MD3, Aseel Alzahrani, PharmD4, Abdulrahman Nugali, PharmD5, Wedad Alnemari, MSc, Pharm.D6.
1Tawam Hospital, Abu Dhabi, United Arab Emirates, 2Sheikh khalifa Medical city , Abu dhabi, Abu Dhabi, United Arab Emirates, 3Sheikh khalifa Medical city, Abu dhabi, United Arab Emirates, 4HEPA Solutions, Riyadh, Saudi Arabia, 5HEPA Solutions, Jeddah, Saudi Arabia, 6Sanofi, Riyadh, Saudi Arabia.
1Tawam Hospital, Abu Dhabi, United Arab Emirates, 2Sheikh khalifa Medical city , Abu dhabi, Abu Dhabi, United Arab Emirates, 3Sheikh khalifa Medical city, Abu dhabi, United Arab Emirates, 4HEPA Solutions, Riyadh, Saudi Arabia, 5HEPA Solutions, Jeddah, Saudi Arabia, 6Sanofi, Riyadh, Saudi Arabia.
OBJECTIVES: Fitusiran is a subcutaneous small-interfering RNA therapy that restores hemostasis by reducing antithrombin production in patients with hemophilia A or B, irrespective of inhibitor status. This study estimated the budget impact of introducing fitusiran for eligible pediatric and adult patients (≥12 years) with hemophilia A and B in the UAE, from a public payer perspective.
METHODS: A 5-year prevalence-based budget impact model was developed comparing two scenarios: a world without fitusiran in which patients receive current standard-of-care treatments, and a world with fitusiran in which fitusiran captures a projected market share uptake in Year 1 to Year 5. The eligible population was estimated at 78 patients in Year 1 (Hemophilia A: 60; Hemophilia B: 19), growing to 94 by Year 5. Drug acquisition costs were sourced from the TAMM Abu Dhabi CIF price database (December 2025), administration, and non-drug disease management costs obtained from public hospital business centers and validated by local experts. All costs are reported in USD (1 USD = 3.675 AED). Deterministic sensitivity analysis was conducted.
RESULTS: Introduction of fitusiran was projected to generate cumulative 5-year budget savings of $7.9M compared to a world without fitusiran (total costs: $174.5M vs. $182.4M). Annual savings grew from $768,203 in Year 1 to $2.5M by Year 5, driven predominantly by reductions in pharmacy, medication, and administration costs ($7.9M saved over 5 years). The drug acquisition cost was offset by Pharmacy, medication and administration costs across both hemophilia types and inhibitor subgroups.
CONCLUSIONS: Fitusiran adoption in the UAE is projected to generate progressive budget savings for public payers over a 5-year horizon, with growing annual savings driven by reductions in pharmacy, medication and administration costs across hemophilia A and B subpopulations. These findings support formulary inclusion and managed-access reimbursement considerations for fitusiran within the UAE healthcare system.
METHODS: A 5-year prevalence-based budget impact model was developed comparing two scenarios: a world without fitusiran in which patients receive current standard-of-care treatments, and a world with fitusiran in which fitusiran captures a projected market share uptake in Year 1 to Year 5. The eligible population was estimated at 78 patients in Year 1 (Hemophilia A: 60; Hemophilia B: 19), growing to 94 by Year 5. Drug acquisition costs were sourced from the TAMM Abu Dhabi CIF price database (December 2025), administration, and non-drug disease management costs obtained from public hospital business centers and validated by local experts. All costs are reported in USD (1 USD = 3.675 AED). Deterministic sensitivity analysis was conducted.
RESULTS: Introduction of fitusiran was projected to generate cumulative 5-year budget savings of $7.9M compared to a world without fitusiran (total costs: $174.5M vs. $182.4M). Annual savings grew from $768,203 in Year 1 to $2.5M by Year 5, driven predominantly by reductions in pharmacy, medication, and administration costs ($7.9M saved over 5 years). The drug acquisition cost was offset by Pharmacy, medication and administration costs across both hemophilia types and inhibitor subgroups.
CONCLUSIONS: Fitusiran adoption in the UAE is projected to generate progressive budget savings for public payers over a 5-year horizon, with growing annual savings driven by reductions in pharmacy, medication and administration costs across hemophilia A and B subpopulations. These findings support formulary inclusion and managed-access reimbursement considerations for fitusiran within the UAE healthcare system.
Conference/Value in Health Info
2026-11, ISPOR Europe 2026, Vienna, Austria
Value in Health, Volume 29, Issue 12S
Code
EE432
Topic
Economic Evaluation, Health Technology Assessment, Real World Data & Information Systems
Topic Subcategory
Budget Impact Analysis
Disease
No Additional Disease & Conditions/Specialized Treatment Areas, Systemic Disorders/Conditions (Anesthesia, Auto-Immune Disorders (n.e.c.), Hematological Disorders (non-oncologic), Pain)